GLP-1 and Hyperoxia for Organ Protection in Heart Surgery

Inclusion Criteria: * Before any study-specific procedure, including assessments for screening, the appropriate written informed consent must be obtained. * ≥ 18 years of age at the time of signing informed consent. * Ischemic heart disease requiring coronary artery bypass grafting (multi-vessel coronary artery disease or coronary anatomy not suitable for percutaneous coronary intervention) and/or aortic valve disease scheduled for aortic valve replacement, irrespective of other concomitant valve surgery. Exclusion Criteria: * Active treatment with GLP-1 agonists * Obstructive hypertrophic cardiomyopathy, active myocarditis, constrictive pericarditis, untreated hypothyroidism or hyperthyroidism or history of or active acute pancreatitis. * Acute (i.e. off hours, within hours surgery), Sub-acute surgery (i.e. the following days) are eligible. * Known allergy towards Exenatide/Byetta or albumin (vehicle). * On the urgent waiting list for a heart transplant (UNOS category 1A or 1B, or equivalent). Patients on the non-urgent waiting list for a heart transplant (UNOS category 2 or 7, or equivalent) are eligible for inclusion in the study. * Recipient of any major organ transplant (e.g. lung, liver, heart) * Receiving or has received cytotoxic or cytostatic chemotherapy and/or radiation therapy for treatment of a malignancy within 6 month before randomization or clinical evidence of current malignancy, with the following exceptions: basal or squamous cell carcinoma of the skin, …